BeOne Medicines (NASDAQ:ONC) COO Xiaobin Wu Sells 6,009 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 6,009 shares of the company’s stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $380.54, for a total value of $2,286,664.86. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Xiaobin Wu also recently made the following trade(s):

• On Wednesday, November 12th, Xiaobin Wu sold 10,000 shares of BeOne Medicines stock. The shares were sold at an average price of $356.02, for a total transaction of $3,560,200.00.

BeOne Medicines Trading Down 0.7%

NASDAQ ONC traded down $2.54 during trading on Friday, hitting $365.82. The company had a trading volume of 230,040 shares, compared to its average volume of 390,826. The company’s fifty day moving average is $329.42 and its 200-day moving average is $290.65. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $170.99 and a one year high of $381.50. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03. The company has a market cap of $40.12 billion, a price-to-earnings ratio of 717.29 and a beta of 0.31.

Wall Street Analysts Forecast Growth

Several analysts have commented on ONC shares. Royal Bank Of Canada raised their price objective on shares of BeOne Medicines from $374.00 to $395.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Barclays started coverage on BeOne Medicines in a research report on Thursday, September 18th. They issued an “overweight” rating and a $385.00 target price for the company. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Friday, October 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday, October 8th. Finally, Zacks Research downgraded BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 28th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $357.33.

Institutional Trading of BeOne Medicines

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Anchor Investment Management LLC bought a new position in shares of BeOne Medicines in the second quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd purchased a new position in BeOne Medicines in the 2nd quarter worth approximately $28,000. Daiwa Securities Group Inc. bought a new position in BeOne Medicines in the 2nd quarter valued at approximately $35,000. Farther Finance Advisors LLC bought a new position in BeOne Medicines in the 2nd quarter valued at approximately $39,000. Finally, Signaturefd LLC purchased a new stake in BeOne Medicines during the 2nd quarter valued at $49,000. 48.55% of the stock is currently owned by institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.